In early trading on Friday, shares of KaloBios were up more than
100%.

Last Friday, KaloBios said
it would wind down its operations, and since then the stock has
gone from under $1.00 per share to $21.00.

Shkreli first came into the public eyeearlier
this fallwhen presidential candidate Hillary Clinton
called out the pricing practices of his company, Turing
Pharmaceuticals, which raised the price of one drug by
5,000%.

KaloBios announced Thursday that it has received a
commitment from Shkreli and other investors for an
equity investment of at least $3 million, with this
group also committingto a $10 million
equity-financing facility.So Shkreli and his
associates gave KaloBios a lifeline and now he's getting a chance
to run the place.

Shkreli said in a statement that KaloBios plans to go
forward with the development of its leukemia treatment.